8 |
Bivalirudin on Trial: Rationale and Status of ISAR-REACT 3 and 4 |
Adnan Kastrati |
Sep. 14. 07 |
7 |
ACUITY: One Year Outcome of ACUITY Trial |
Roxana Mehran |
May. 25. 07 |
6 |
ACUITY PCI: A Prospective Trial of Patients With Acute Coronary Syndromes Undergoing PCI After Randomization to Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs Bivalirudin With or Without Glycoprotein IIb/IIIa Inhibitors: 30-Day Clinical and Angiographic Core Laboratory Results |
Gregg W. Stone |
May. 25. 07 |
5 |
Lipid Treatment in Post PCI Patients |
Donghoon Choi |
Nov. 10. 06 |
4 |
Tirofiban and STEMI Management: A Future Perspective |
Gian Battista Danzi |
Oct. 13. 06 |
3 |
Optimizing Outcomes of Primary PCI: From CADILLAC to HORIZONS |
Gregg W. Stone |
Aug. 19. 05 |
2 |
LMWHs in the Setting of PCI |
Philippe Garot |
Feb. 04. 05 |
1 |
Integration of New Antithrombotic Approaches During Percutaneous Coronary Intervention: Direct Thrombin Inhibitors, GP IIb/IIa Antagonists and Thienopyridines(REPLACE II) |
A. Michael Lincoff |
Sep. 24. 04 |